Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dasatinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 114 for your search:
Start Over
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-400, 2011-006180-21, NCT01660906
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-034, NCT00123474
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-056, 2006-005712-27, NCT00481247
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-2009-00312, CDR0000600217, COG-AALL0622, AALL0622, U10CA098543, NCT00720109
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-227, 2008-000701-11, NCT00744497
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-031, NCT00337454
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-086, NCT00439270
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-138, NCT00482703
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: 244-07-FB, BMS Protocol 180129, NCT00550615
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0900, NCI-2010-01575, NCT00566618
A Phase I/II Study of Dasatinib and Dacarbazine
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15256, 106128, CA180-092, NCT00597038
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 07053, P30CA033572, CHNMC-07053, CA180 121, CDR0000617760, NCT00788125
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 90
Sponsor: Other
Protocol IDs: 08-122, NCT00820170
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: 2008-0353, NCI-2012-01653, NCT00826449
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 11-08, NCT00850382
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCCTG-N0877, NCI-2009-01179, CDR0000637854, U10CA025224, N0877, NCT00869401
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor: Other
Protocol IDs: J08101, CA180123, NCT00882583
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ALSSMBC0804, NCT00924352
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCSD 110054 - Prev 080422, NCT00949988
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-323, 2010-019480-11, NCT01218477
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: 2011-0254, NCI-2011-03531, NCT01460498
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Phase: Phase II
Type: Treatment
Status: Closed
Age: 70 and under
Sponsor: NCI, Other
Protocol IDs: 1581.00, NCI-2010-00131, P30CA015704, P01CA078902, FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
Imatinib Mesylate or Dasatinib in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00764, S0325, U10CA032102, U01CA180888, SWOG-S0325, ECOG-S0325, NCT00070499
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-015, NCT00101595
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-005, NCT00101647
Start Over